{
    "clinical_study": {
        "@rank": "94055", 
        "arm_group": [
            {
                "arm_group_label": "Placebo", 
                "arm_group_type": "Placebo Comparator", 
                "description": "Placebo matching LY3023703 administered orally, once daily (QD), for 28 days"
            }, 
            {
                "arm_group_label": "LY3023703", 
                "arm_group_type": "Experimental", 
                "description": "Escalating doses (2.5 milligram [mg] up to 30 mg) of LY3023703 administered orally, QD, for 28 days"
            }, 
            {
                "arm_group_label": "Celecoxib", 
                "arm_group_type": "Active Comparator", 
                "description": "400 mg celecoxib administered orally, QD, for 28 days.  (Positive control.)"
            }
        ], 
        "brief_summary": {
            "textblock": "This is a study of LY3023703 in healthy participants.  The purposes of this study are to\n      look at safety, how well the study drug is tolerated, how much of the study drug gets into\n      the blood stream and how long it takes the body to remove the study drug.  The effects of\n      LY3023703 on blood pressure after 28 days of dosing will be studied.  Information about any\n      side effects that occur will be collected.  The study is expected to last 21 weeks."
        }, 
        "brief_title": "A Multiple Dose Study of LY3023703 in Healthy Participants", 
        "completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "condition": "Healthy Volunteers", 
        "eligibility": {
            "criteria": {
                "textblock": "Inclusion Criteria:\n\n          -  Overtly healthy individuals based on the history and physical examinations as\n             determined by the investigator\n\n          -  Are normotensive (defined as supine systolic blood pressure [BP] less than 140\n             millimeters of mercury [mm Hg] and diastolic BP less than 90 mm Hg without the use of\n             any antihypertensives) or results that are judged to be not clinically significant by\n             the investigator\n\n        Exclusion Criteria:\n\n          -  Have presence of clinically significant active bleeding or history of bleeding\n             diathesis at the time of screening\n\n          -  Have presence of active peptic ulcer disease, gastro-intestinal (GI) bleeding,\n             chronic gastritis, inflammatory bowel disease, or chronic diarrhea\n\n          -  Have evidence of other chronic liver disease\n\n          -  Have any use of nonsteroidal anti-inflammatory drugs (NSAIDs), celecoxib, aspirin, or\n             acetaminophen (at doses greater than 1 gram per day [g/day] within 14 days of\n             admission\n\n          -  Have greater than 1 plus pretibial pitting edema or 2 plus ankle or pedal edema"
            }, 
            "gender": "Both", 
            "healthy_volunteers": "Accepts Healthy Volunteers", 
            "maximum_age": "60 Years", 
            "minimum_age": "18 Years"
        }, 
        "enrollment": {
            "#text": "90", 
            "@type": "Anticipated"
        }, 
        "firstreceived_date": "May 6, 2013", 
        "has_expanded_access": "No", 
        "id_info": {
            "nct_id": "NCT01849055", 
            "org_study_id": "14708", 
            "secondary_id": "I6H-MC-MCBB"
        }, 
        "intervention": [
            {
                "arm_group_label": "Placebo", 
                "description": "Administered orally", 
                "intervention_name": "Placebo", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "LY3023703", 
                "description": "Administered orally", 
                "intervention_name": "LY3023703", 
                "intervention_type": "Drug"
            }, 
            {
                "arm_group_label": "Celecoxib", 
                "description": "Administered orally", 
                "intervention_name": "Celecoxib", 
                "intervention_type": "Drug"
            }
        ], 
        "intervention_browse": {
            "mesh_term": "Celecoxib"
        }, 
        "is_fda_regulated": "Yes", 
        "is_section_801": "No", 
        "lastchanged_date": "December 16, 2013", 
        "location": {
            "facility": {
                "address": {
                    "city": "Evansville", 
                    "country": "United States", 
                    "state": "Indiana", 
                    "zip": "47710"
                }, 
                "name": "For additional information regarding investigative sites for this trial, contact 1-877-CTLILLY (1-877-285-4559, 1-317-615-4559) Mon - Fri from 9 AM to 5 PM Eastern Time (UTC/GMT - 5 hours, EST), or speak with your personal physician."
            }
        }, 
        "location_countries": {
            "country": "United States"
        }, 
        "number_of_arms": "3", 
        "official_title": "A Multiple-Dose, Dose-Escalation Study to Evaluate the Safety and Tolerability of LY3023703 in Healthy Subjects", 
        "overall_official": {
            "affiliation": "Eli Lilly and Company", 
            "last_name": "Call 1-877-CTLILLY (1-877-285-4559) or 1-317-615-4559 Mon - Fri 9 AM - 5 PM Eastern time (UTC/GMT - 5 hours, EST)", 
            "role": "Study Director"
        }, 
        "overall_status": "Completed", 
        "oversight_info": {
            "authority": "United States: Food and Drug Administration", 
            "has_dmc": "No"
        }, 
        "phase": "Phase 1", 
        "primary_completion_date": {
            "#text": "December 2013", 
            "@type": "Actual"
        }, 
        "primary_outcome": {
            "measure": "Number of Participants with One or More Serious Adverse Event(s) (SAEs) Considered by the Investigator to be Related to Study Drug Administration", 
            "safety_issue": "Yes", 
            "time_frame": "Baseline to study completion (approximately 6 weeks not including screening)"
        }, 
        "required_header": {
            "download_date": "ClinicalTrials.gov processed this data on June 04, 2014", 
            "link_text": "Link to the current ClinicalTrials.gov record.", 
            "url": "http://clinicaltrials.gov/show/NCT01849055"
        }, 
        "responsible_party": {
            "responsible_party_type": "Sponsor"
        }, 
        "secondary_outcome": [
            {
                "measure": "Pharmacokinetics: Area Under the Concentration Versus Time Curve (AUC) of LY3023703", 
                "safety_issue": "No", 
                "time_frame": "Post first dose on day 1 through 28 days"
            }, 
            {
                "measure": "Pharmacokinetics: Maximum Concentration (Cmax) of LY3023703", 
                "safety_issue": "No", 
                "time_frame": "Post first dose on day 1 through 28 days"
            }, 
            {
                "measure": "Pharmacokinetics: Time of Maximum Concentration (tmax) of LY3023703", 
                "safety_issue": "No", 
                "time_frame": "Post first dose on day 1 through 28 days"
            }, 
            {
                "measure": "Change from Baseline to Day 27 in Blood Pressure (BP)", 
                "safety_issue": "No", 
                "time_frame": "Baseline, Day 27"
            }
        ], 
        "source": "Eli Lilly and Company", 
        "sponsors": {
            "lead_sponsor": {
                "agency": "Eli Lilly and Company", 
                "agency_class": "Industry"
            }
        }, 
        "start_date": "May 2013", 
        "study_design": "Allocation: Randomized, Endpoint Classification: Safety Study, Intervention Model: Parallel Assignment, Masking: Double Blind (Subject, Investigator), Primary Purpose: Basic Science", 
        "study_type": "Interventional", 
        "verification_date": "December 2013"
    }
}